The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...

The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

The oversubscribed Series C financing round will support the clinical development of in vivo CAR-T cells for oncology and autoimmune diseases. The U.S. biotech company Umoja Biopharma announced this ...

Josh Gissing is Cluster Head (UK, Ireland & Nordics) for Biocon Biologics: a biosimilars company whose business model seeks to make biologic therapies affordable, accessible and available to all. He ...

The Swedish biotech hopes its precision therapy will help patients with advanced solid tumors who currently have few treatment options. Neogap is developing a personalized Tumor Trained Lymphocyte ...

The French biotech company Nanobiotix announced today that it has dosed the first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating its potentially ...